Overview

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of Sintilimab combined with Chidamide in the treatment of relapsed/refractory cutaneous T-cell lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborators:

Beijing Longfu Hospital
Dongzhimen Hospital, Beijing
Peking University Third Hospital